TY - JOUR
T1 - Bone markers and their prognostic value in metastatic bone disease
T2 - Clinical evidence and future directions
AU - Coleman, Robert
AU - Brown, Janet
AU - Terpos, Evangelos
AU - Lipton, Allan
AU - Smith, Matthew R.
AU - Cook, Richard
AU - Major, Pierre
N1 - Funding Information:
Dr. Coleman has received consultancy fees, speaker fees, and research funding from Novartis and has given expert testimony on their behalf.
Funding Information:
Funding for medical editorial assistance was provided by Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, USA.
PY - 2008/11
Y1 - 2008/11
N2 - Background: Bone metastases are prevalent among patients with advanced solid tumors. Metastatic bone disease alters bone homeostasis, resulting in reduced bone integrity and, consequently, increased skeletal complications. Biochemical markers of bone metabolism may meet an unmet need for useful, noninvasive, and sensitive surrogate information for following patients' skeletal health. Materials and methods: Data for this review were identified by searches of PubMed, and references from relevant articles using the search terms "bone markers" or individual bone marker nomenclature, "cancer," and "metastases." Abstracts and reports from meetings were included only when they related directly to previously published work. Only papers published in English between 1990 and 2007 were included. Results: Recent retrospective analyses with bisphosphonates, and particularly with zoledronic acid, have shown significant correlations between biochemical markers of bone metabolism levels and clinical outcomes, especially for bone resorption markers. Clinical results for biochemical markers of bone formation and resorption and other emerging markers of bone metabolism including bone sialoprotein, receptor-activator of nuclear factor-κB ligand, osteoprotegerin, and other markers are presented. However, biochemical markers of bone metabolism are not yet an established surrogate endpoint for treatment efficacy. Conclusions: Biochemical markers of bone metabolism may allow physicians to identify which patients with metastatic bone disease are at high risk for skeletal-related events or death and who may be responding to therapy. Prospective randomized clinical trials are underway to further assess the utility of markers of bone metabolism in patients with bone metastases.
AB - Background: Bone metastases are prevalent among patients with advanced solid tumors. Metastatic bone disease alters bone homeostasis, resulting in reduced bone integrity and, consequently, increased skeletal complications. Biochemical markers of bone metabolism may meet an unmet need for useful, noninvasive, and sensitive surrogate information for following patients' skeletal health. Materials and methods: Data for this review were identified by searches of PubMed, and references from relevant articles using the search terms "bone markers" or individual bone marker nomenclature, "cancer," and "metastases." Abstracts and reports from meetings were included only when they related directly to previously published work. Only papers published in English between 1990 and 2007 were included. Results: Recent retrospective analyses with bisphosphonates, and particularly with zoledronic acid, have shown significant correlations between biochemical markers of bone metabolism levels and clinical outcomes, especially for bone resorption markers. Clinical results for biochemical markers of bone formation and resorption and other emerging markers of bone metabolism including bone sialoprotein, receptor-activator of nuclear factor-κB ligand, osteoprotegerin, and other markers are presented. However, biochemical markers of bone metabolism are not yet an established surrogate endpoint for treatment efficacy. Conclusions: Biochemical markers of bone metabolism may allow physicians to identify which patients with metastatic bone disease are at high risk for skeletal-related events or death and who may be responding to therapy. Prospective randomized clinical trials are underway to further assess the utility of markers of bone metabolism in patients with bone metastases.
UR - http://www.scopus.com/inward/record.url?scp=53649083433&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=53649083433&partnerID=8YFLogxK
U2 - 10.1016/j.ctrv.2008.05.001
DO - 10.1016/j.ctrv.2008.05.001
M3 - Review article
C2 - 18579314
AN - SCOPUS:53649083433
SN - 0305-7372
VL - 34
SP - 629
EP - 639
JO - Cancer Treatment Reviews
JF - Cancer Treatment Reviews
IS - 7
ER -